Weixinkang's wholly-owned subsidiary Baiyi Pharmaceutical has received the drug registration certificate for Multivitamin for Injection (12) approved and issued by the National Medical Products Administration. The product specification is 5 ml per vial, registered as a Category 4 chemical drug, and deemed to have passed the consistency evaluation. Multivitamin for Injection (12) is an intravenous vitamin supplement indicated for adult and pediatric patients aged 11 years and older who require vitamin supplementation via injection when oral nutrition is contraindicated, impossible, or insufficient.
Tibet Weixinkang Medicine Co LtdSubsidiary obtains drug registration certificate for Multivitamin for Injection (12), a new product approval.
Baiyi Pharmaceutical receives drug registration certificate for Multivitamin for Injection (12).
